Pancreatic Disorders & Therapy
Open Access
ISSN: 2165-7092
+44 1478 350008
ISSN: 2165-7092
+44 1478 350008
Szcześniak P
Poland
Research Article
Serum level of Urokinase Plasminogen Activator (uPA) Correlates with the Survival of Patients with Pancreatic Ductal Adenocarcinoma (PDAC)
Author(s): Winter K, Szcześniak P, Bulska M, Kumor-Kisielewska A, Durko Ł, Gąsiorowska A, Orszulak-Michalak D and Małecka Panas EWinter K, Szcześniak P, Bulska M, Kumor-Kisielewska A, Durko Ł, Gąsiorowska A, Orszulak-Michalak D and Małecka Panas E
Background: Urokinase plasminogen activator (uPA) is a serine protease which transforms inactive plasminogen into active plasmin. UPA plays an important role in neoplasm progression, cell growth and metastases through degradation of proteins in basement membranes and extracellular matrix. The aim of the study was the analysis of serum uPA concentration in patients suffering from pancreatic ductal adenocarcinoma (PDAC) and chronic pancreatitis (CP) in order to determine its possible diagnostic and prognostic value.
Methods: A study group involved 90 patients: 40 patients with PDAC, 30 patients with CP and 20 healthy individuals. UPA serum concentration was evaluated with ELISA.
Results: We observed the threefold increase of uPA serum concentration in patients with PDAC (3,23 ng/ml), twofold increase of uPA serum concent.. View More»
DOI:
10.4172/2165-7092.1000163